2 Min Read
(Reuters) - Johnson & Johnson on Tuesday said it expected to report eagerly-awaited data on its COVID-19 vaccine early next week, and that it would be able to meet the delivery target for doses to countries with which it had signed supply agreements.
Slideshow ( 2 images )
Public health officials are increasingly counting on single-dose options like the one being tested by J&J to simplify and boost inoculations given the complications and slower-than-hoped rollout of authorized vaccines from Pfizer Inc and Moderna Inc, which require second shots weeks after the first.
The company forecast 2021 profit well above Wall Street estimates, and its shares rose 3.4% to $171.55.
Moderna: 30.4M COVID-19 Vaccines Supplied To US
Johnson & Johnson, another US pharmaceutical firm, to report phase 3 trial results next week. Moderna announced Tuesday that it has supplied 30.4 million doses of a coronavirus vaccine to the US government.
The US pharmaceutical company said it is on track to deliver 100 million doses by the end of the first quarter with 200 million doses available by the end of the second quarter.
As part of former President Donald Trump administration s Operation Warp Speed, the US agreed to purchase 200 million doses of Moderna s vaccine with options for an additional purchase of 300 million doses.
The vaccine received emergency use authorization Dec. 18 from the US Food and Drug Administration (FDA) and the company began supplying its first batch shortly afterward.